Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9RC7D)

• Drug Name: SAGE-718 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]
Parkinson disease	8A00.0	Phase 2	[2]
Schizophrenia	6A20	Phase 1	[3]

• Cross-matching ID:
  PubChem CID: 86305217
  TTD Drug ID: DM9RC7D

Molecule-Related Drug Atlas

Drug(s) Targeting N-methyl-D-aspartate receptor (NMDAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Glutamic Acid	DM4PUDW	Schizophrenia	6A20	Approved	[4]
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[5]
Benzphetamine	DMIJATC	Obesity	5B81	Approved	[6]
Ketamine	DMT5HA4	Anaesthesia	9A78.6	Approved	[7]
Felbamate	DM1V5ZS	Epilepsy	8A60-8A68	Approved	[8]
Memantine	DMD9WSC	Alzheimer disease	8A20	Approved	[9]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[10]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[11]
Magnesium Sulfate	DMVEK07	Acute pain	MG31	Approved	[12]
Magnesium	DMU4ORS	Ischemic stroke	8B11.5Z	Approved	[13]
L-Glutamic Acid	DM4PUDW	Schizophrenia	6A20	Approved	[4]
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[5]
Benzphetamine	DMIJATC	Obesity	5B81	Approved	[6]
Ketamine	DMT5HA4	Anaesthesia	9A78.6	Approved	[7]
Felbamate	DM1V5ZS	Epilepsy	8A60-8A68	Approved	[8]
Memantine	DMD9WSC	Alzheimer disease	8A20	Approved	[9]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[10]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[11]
Magnesium Sulfate	DMVEK07	Acute pain	MG31	Approved	[12]
Magnesium	DMU4ORS	Ischemic stroke	8B11.5Z	Approved	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Modulator	[3]

References

• [1] ClinicalTrials.gov (NCT04602624) An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04476017) A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI). U.S. National Institutes of Health.
• [3] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [4] Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
• [5] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [6] Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
• [7] Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
• [8] Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
• [9] The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
• [10] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [11] Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
• [12] Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
• [13] Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.